MétaCan
Menu
Back to cohort

766 A clinical trial to evaluate the safety, tolerability and preliminary efficacy of VG161 in combination with Nivolumab in patients with advanced pancreatic cancer

2023· article· en· W4388048272 on OpenAlexaff
Yinan Shen, Aijun Qin, Yiting Qiu, Xinyan Jin, Wei Song, Fang Tian, Xingmei Liang, Yuwei Li, David S.P. Tan, Ronghua Zhao, Xueli Bai, Tingbo Liang

Bibliographic record

VenueRegular and Young Investigator Award Abstracts · 2023
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicVirus-based gene therapy research
Canadian institutionsVancouver Biotech (Canada)
Fundersnot available
KeywordsTolerabilityMedicinePharmacodynamicsNivolumabOncolytic virusInternal medicinePharmacokineticsGastroenterologyRefractory (planetary science)Pancreatic cancerAdverse effectCancerOncologyUrologyPharmacologyImmunotherapyBiology

Abstract

fetched live from OpenAlex

<h3>Background</h3> VG161 is a non-attenuated HSV-1 Oncolytic virus (OV) with IL-12, IL-15, IL-15Ra and PD-L1 blocking payloads. Here we report an open label, study to evaluate the safety, pharmacokinetics (PK), and biologic effects of VG161 in patients (pts) with advanced pancreatic cancer progressed after standard of care. The study is actively recruiting. NCT05162118. <h3>Methods</h3> Dose escalation follows a 3+3 design at 3 dose levels as VG161 intratumoral injections on days 1,2,3 and Nivolumab treatment on days 22 and 28 of each 28 days treatment cycle. PK and viral shedding (DNA), samples from biopsies, blood, urine, and swabs from injection site and other anatomical locations were analyzed by PCR. Changes of cytokines and lymphocyte subsets in blood were also observed as pharmacodynamic parameters. Samples were harvested on C1D1, C1D7 and C2D1 which were analyzed by single-cell sequencing. <h3>Results</h3> As of 31 May 2023, 13 pts received doses of 1.5x10<sup>8</sup> PFU, 2.0x10<sup>8</sup> PFU and 3.0x10<sup>8</sup> PFU. 10 males and 3 females with the median age of 58 years were enrolled. 76.9% were PD(L)1 refractory,46.2% had 2 Prior lines of therapy and 13% ≥3. No Dose Limiting Toxicities were observed. Any grade treatment-related AEs (TRAEs) was 5.7%. The most common TRAEs were all grade 1 and 2. 9 pts had SAEs, including 1 pts (7%) with a related SAE (cytokine release syndrome). No TRAEs leading to dose reduction and treatment discontinuation. No pts had positive viral shedding. 11 pts were efficacy evaluable; ORR 9.1% and DCR 23.1% based on RECIST v1.1. Tumor shrinkage was also observed in non-injected lesions demonstrating an abscopal effect. According to the results of single cell data analysis, patients with advanced pancreatic cancer treated with VG161 remodeled the tumor microenvironment in the tumor, torqued from a cold tumor to a hot tumor, reduced the number of tumor cells, and significantly increased T and NK cell infiltration (T cells increased by 15% in injected lesions and NK cells increased by 3% in non-injected lesions after VG161 dosing). Moreover, patients were also more sensitive to subsequent immunosuppressive therapy. <h3>Conclusions</h3> VG161 can significantly improve the immune microenvironment and provide favorable conditions for the combination of nivolumab. <h3>Trial Registration</h3> NCT05162118 <h3>Ethics Approval</h3> Approval Letter of Clinical Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University. ID:IIT20210108C

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.216
Threshold uncertainty score0.439

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.331
Teacher spread0.305 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueRegular and Young Investigator Award AbstractsSame topicVirus-based gene therapy researchFrench-language works237,207